Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

M. Kantarjian, Hagop; Thomas, Xavier; Dmoszyńska, Anna; Wierzbowska, Agnieszka; Mazur, Grzegorz; Mayer, Jiří; Gau, Jyh-Pyng; Chou, Wen‐Chien; Buckstein, Rena; Čermák, Jaroslav; Kuo, Ching-Yuan; Oriol, Albert; Ravandi, Farhad; Faderl, Stefan; Delaunay, Jacques; Lysák, Daniel; D. Minden, Mark; Arthur, Christopher

doi:10.1200/jco.2011.38.9429

Public

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Published in Journal of Clinical Oncology • Jun 12, 2012

Authors:

Hagop M. Kantarjian

Xavier Thomas

Anna Dmoszyńska

Abstract

PURPOSE: This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics. PATIENTS AND METHODS: Patients (N = 485) age ≥...

Subject

Medicine

Decitabine

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!